P00797 (RENI_HUMAN) Homo sapiens (Human)
Renin UniProtKBInterProSTRINGInteractive Modelling
It is possible new templates exist for this target since these models were created.
However, an attempt to improve models for this target was made on 2025-06-20. The outcome - failed for technical reasons.
Available Structures
91 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Crystal structure of human prorenin |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of the complex of human angiotensinogen and renin at 2.55 Angstrom |
Heteromer P01019; | 99.7 | 1×NAG; 1×NAG; 10×SO4; 1×GOL; | |||
| Crystal structure of human angiotensinogen complexed with renin |
Heteromer P01019; | 100.0 | ||||
| Crystal Structure of Human Renin Complexed with Inhibitor | homo-6-mer | 100 | 3×7IG; | |||
| Crystal Structure of Human Renin Complexed with Inhibitor | homo-6-mer | 100 | 6×LIX; 3×CIT; | |||
| Crystal Structure of Human Renin Complexed with Inhibitors | homo-6-mer | 100 | 6×LIY; | |||
| Crystal Structure of Renin with Inhibitor 3 | homo-6-mer | 100.0 | 6×C47; | |||
| Crystal structure at 2.6A of human prorenin | homo-2-mer | 100.0 | 2×NAG; 10×SO4; | |||
| HIGH RESOLUTION CRYSTAL STRUCTURES OF RECOMBINANT HUMAN RENIN IN COMPLEX WITH POLYHYDROXYMONOAMIDE … | homo-2-mer | 100.0 | 2×NAG; 2×03D; | |||
| Optimization of Orally Bioavailable Alkyl Amine Renin Inhibitors | homo-2-mer | 100 | 1×NAG; 4×22X; 1×NAG; | |||
| Design and optimization of new piperidines as renin inhibitors | homo-2-mer | 100 | 1×NAG; 1×LPO; | |||
| Design and optimization of new piperidines as renin inhibitors | homo-2-mer | 100 | 1×NAG; 1×LPQ; | |||
| Design and optimisation of new piperidines as renin inhibitors | homo-2-mer | 100 | 1×NAG; 1×LPN; | |||
| CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS | homo-2-mer | 100.0 | 2×0IU; | |||
| CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS | homo-2-mer | 100.0 | 2×0QB; | |||
| Crystal Structure of Renin with Inhibitor 8 | homo-2-mer | 100.0 | 2×C39; | |||
| THE CRYSTAL STRUCTURE OF RECOMBINANT GLYCOSYLATED HUMAN RENIN ALONE AND IN COMPLEX WITH A TRANSITIO… | homo-2-mer | 100.0 | 2×NAG; 2×C60; | |||
| Human renin/PF02342674 complex | homo-2-mer | 100 | 2×UA4; | |||
| Design and Preparation of Potent, Non-Peptidic, Bioavailable Renin Inhibitors | monomer | 100.0 | 1×A7T; 2×NAG; | |||
| Structure-based design of 4-hydroxy-3,5-substituted piperidines as direct renin inhibitors | monomer | 100.0 | 1×DMS; 1×NAG; 1×PO4; 1×2Y9; | |||
| Human renin in complex with compound2 | monomer | 100.0 | 1×NAG; 1×UNL; | |||
| Structure-Based Optimization of Potent 4- and 6-Azaindole-3-Carboxamides as Renin Inhibitors | monomer | 100 | 1×NAG; 3×GOL; 2×S53; | |||
| Crystal Structure of Renin with Inhibitor 10 (Aliskiren) | monomer | 100.0 | 1×NAG; 1×C41; | |||
| Human renin in complex with compound1 | monomer | 100 | 1×NAG; 1×UNL; | |||
| Crystal structure of renin in complex with NVP-AMQ838 (compound 5) | monomer | 100.0 | 1×NAG; 1×0LR; | |||
| Crystal structure of renin in complex with NVP-BCH965 (compound 9) | monomer | 100.0 | 1×NAG; 1×0MJ; 2×SO4; | |||
| Crystal structure of renin in complex with PKF909-724 (compound 3) | monomer | 100.0 | 1×NAG; 2×0LU; 1×SO4; | |||
| Crystal structure of renin in complex with NVP-AYL747 (compound 5) | monomer | 100.0 | 1×NAG; 1×0M3; 2×SO4; | |||
| Human renin in complex with compound 5 | monomer | 100 | 1×NAG; 1×HHE; | |||
| Human renin in complex with compound3 | monomer | 100 | 1×NAG; 1×UNL; | |||
| Human renin in complex with inhibitor 7 | monomer | 100.0 | 1×NAG; 1×VYE; | |||
| Crystal structure of renin in complex with NVP-BBV031 (compound 6) | monomer | 100.0 | 1×NAG; 1×0ME; 1×SO4; | |||
| Human renin in complex with inhibitor 9 | monomer | 100.0 | 1×NAG; 1×VYF; | |||
| Human renin in complex with compound 18 | monomer | 100 | 1×NAG; 1×R32; | |||
| Human renin in complex with inhibitor 6 | monomer | 100.0 | 1×NAG; 1×VYD; | |||
| Human renin in complex with compound 8 | monomer | 100 | 1×NAG; 1×R31; | |||
| Renin in complex with (S)-1-(3-fluoro-5-(((S)-1-phenylethyl)carbamoyl)benzyl)-4-isopropyl-4-methyl-… | monomer | 100 | 1×NAG; 1×43T; | |||
| Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibi… | monomer | 100.0 | 1×NAG; 1×74U; 1×PEG; | |||
| Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibi… | monomer | 100.0 | 1×NAG; 1×74V; 1×PGE; 2×DMS; | |||
| Renin in complex with (4S)-4-isopropyl-4-methyl-6-oxo-1-(3-(2-oxo-4-phenylpyrrolidin-1-yl)benzyl)te… | monomer | 100 | 1×NAG; 1×70Y; | |||
| Renin in complex with (S)-1-(3-(benzylcarbamoyl)benzyl)-4-isopropyl-4-methyl-6-oxotetrahydropyrimid… | monomer | 100 | 1×NAG; 1×70X; | |||
| RENIN IN COMPLEXED WITH 4-methoxy-3-(3-methoxypropoxy)-N-{[(3S,4S)-4-{[(4-methylphenyl)sulfonyl]ami… | monomer | 100.0 | 1×NAG; 1×3ZK; 1×SO4; | |||
| Crystal structure of renin in complex with NVP-AYZ832 (compound 6a) | monomer | 100.0 | 1×NAG; 2×0LS; 1×SO4; | |||
| RENIN IN COMPLEXED WITH (3S,4S)-4-({[4-methoxy-3-(3-methoxypropoxy)benzoyl](propan-2-yl)amino}methy… | monomer | 100.0 | 1×NAG; 1×3ZN; 1×SO4; | |||
| Novel Approach of Fragment-Based Lead Discovery applied to Renin Inhibitors | monomer | 100.0 | 1×NAG; 1×PG6; 2×DMS; | |||
| Crystal structure of renin in complex with NVP-BGQ311 (compound 12) | monomer | 100.0 | 1×NAG; 1×0N0; 1×SO4; | |||
| RENIN IN COMPLEXED WITH N-({(3S,4S)-4-[(benzylsulfonyl)amino]pyrrolidin-3-yl}methyl)-4-methoxy-3-(3… | monomer | 100.0 | 1×NAG; 1×3ZJ; 1×SO4; | |||
| Crystal structure of renin in complex with NVP-BCA079 (compound 12a) | monomer | 100.0 | 1×NAG; 1×0LT; 1×SO4; | |||
| Crystal structure of renin in complex with GP055321 (compound 4) | monomer | 100.0 | 1×NAG; 1×0M2; | |||
| Crystal structure of renin in complex with compound4 | monomer | 100.0 | 1×NAG; 1×2XF; 1×DMS; 1×SO4; | |||
| New Classes of Potent and Bioavailable Human Renin Inhibitors | monomer | 100.0 | 1×BFX; 1×FMT; 1×NAG; | |||
| Design and Preparation of Potent, Non-Peptidic, Bioavailable Renin Inhibitors | monomer | 100.0 | 1×DMS; 1×NAG; 1×A6T; | |||
| Potent macrocyclic renin inhibitors | monomer | 100.0 | 3×ACT; 2×NA; 1×3OX; | |||
| Design and Preparation of Potent, Non-Peptidic, Bioavailable Renin Inhibitors | monomer | 100.0 | 1×A5T; 1×DMS; 1×NAG; | |||
| Crystal structure of human renin complexed with a novel inhibitor | monomer | 100 | 1×NAG; 1×72X; 4×GOL; 1×CL; | |||
| Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor | monomer | 100.0 | 1×NAG; 1×6VU; 1×PGE; 3×PEG; 8×DMS; | |||
| Clinically Useful Alkyl Amine Renin Inhibitors | monomer | 100 | 1×NAG; 4×CL; 1×RX6; | |||
| Clinically Useful Alkyl Amine Renin Inhibitors | monomer | 100 | 1×NAG; 4×CL; 1×RX5; | |||
| Optimization of 3,5-Disubstitued Piperidine: Discovery of Non-Peptide mimetics as an Orally Active … | monomer | 100.0 | 1×NAG; 1×7EK; 1×PGE; 1×PEG; 3×DMS; | |||
| Human renin in complex with remikiren | monomer | 100.0 | 1×REM; 1×DMS; | |||
| Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibi… | monomer | 100.0 | 1×NAG; 1×74Z; 6×DMS; 1×PEG; 1×1PE; | |||
| Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor | monomer | 100.0 | 1×NAG; 1×6VS; 8×DMS; 2×PEG; | |||
| STRUCTURE OF RECOMBINANT HUMAN RENIN, A TARGET FOR CARDIOVASCULAR-ACTIVE DRUGS, AT 2.5 ANGSTROMS RE… | monomer | 100.0 | 1×NAG; | |||
| Crystal Structure Analysis of Renin-indole-piperazin inhibitor complexes | monomer | 100 | 1×NAG; 1×SSR; | |||
| Alkyl Amine Renin Inhibitors: Filling S1 from S3 | monomer | 100 | 1×NAG; 1×RX0; 2×GOL; | |||
| Crystal Structure of Human Renin in Complex with a biphenylpipderidinylcarbinol | monomer | 100 | 1×NAG; 2×90D; | |||
| Optimization of 3,5-Disubstitued Piperidine: Discovery of Non-Peptide mimetics as an Orally Active … | monomer | 100.0 | 1×NAG; 1×7EJ; 3×DMS; | |||
| Crystal Structure Analysis of Renin-indole-piperazine inhibitor complexes | monomer | 100 | 1×NAG; 1×S51; | |||
| Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibi… | monomer | 100.0 | 1×NAG; 1×74Y; 3×PEG; | |||
| Crystal Structure Analysis of Renin-indole-piperazin inhibitor complexes | monomer | 100 | 1×NAG; 1×S52; | |||
| Crystal Structure of Human Renin in Complex with a biphenylpipderidinylcarbinol | monomer | 100.0 | 1×NAG; 1×9G7; 1×SO4; | |||
| Crystal Structure of Renin with Inhibitor 6 | monomer | 100.0 | 1×C80; | |||
| Crystal Structure of Renin with Inhibitor 9 | monomer | 100.0 | 1×C61; | |||
| Crystal Structure of Human Renin in Complex with a biphenylpipderidinylcarbinol | monomer | 100.0 | 1×NAG; 1×SO4; 2×9JD; | |||
| Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor | monomer | 100.0 | 1×NAG; 1×6VR; | |||
| Crystal Structure of Renin with Inhibitor 7 | monomer | 100.0 | 1×C40; | |||
| X-RAY ANALYSES OF PEPTIDE INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN … | monomer | 100.0 | ||||
| crystal structure of renin-pf00257567 complex | monomer | 100.0 | 1×RPF; | |||
| Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | monomer | 100.0 | 1×7IG; | |||
| Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | monomer | 100.0 | ||||
| crystal structure of Renin-PF00074777 complex | monomer | 100.0 | ||||
| Ketopiperazine-Based Renin Inhibitors: Optimization of the C ring | monomer | 100.0 | ||||
| Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | monomer | 100.0 | 1×L1B; | |||
| Ketopiperazine-Based Renin Inhibitors: Optimization of the C Ring | monomer | 100 | 1×L1A; | |||
| Ketopiperazine-Based Renin Inhibitors: Optimization of the C Ring | monomer | 100 | 1×NAG; 1×3IG; | |||
| Ketopiperazine-Based Renin Inhibitors: Optimization of the C Ring | monomer | 100 | 1×NAG; 1×4IG; | |||
| Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | monomer | 100 | 1×NAG; 1×5IG; | |||
| Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | monomer | 100 | 1×NAG; 1×6IG; | |||
| Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | monomer | 100 | 1×NAG; 1×2IG; | |||
| Ketopiperazine-based renin inhibitors: Optimization of the "C" ring | monomer | 100 | 1×NAG; 1×1IG; | |||
| Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | monomer | 100.0 | 1×4LG; | |||
2 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 2x0b.1.A | monomer | 0.90 | 100.00 | |||
| 4amt.1.B | monomer | 0.77 | 100.00 | |||
2 SWISS-MODEL models built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 2x0b.1.A | monomer | 0.90 | 99.47 | |||
| Isoform 2 | 4amt.1.B | monomer | 0.79 | 100.00 | |||